BC Extra | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

Patients need to control the use of their data. This calls for new policies on transparency and consent, and means establishing systems governing the ownership, collection and agency of those data. Data privacy is probably...
BC Innovations | Feb 8, 2018
Finance

External rethink

As the industry seeks to develop new ways to access external innovation, companies are re-evaluating the value of public-private partnerships, and increasingly turning to other companies for research partnerships in lieu of broad deals with...
BC Week In Review | Oct 6, 2017
Company News

Takeda, Karolinska Institute and Structural Genomics Consortium partner to treat IBD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Karolinska Institute (Stockholm, Sweden) and Structural Genomics Consortium (SGC) (Headington, U.K.) partnered to discover and validate new intervention points to treat inflammatory bowel disease (IBD). Under the deal, Takeda will...
BC Innovations | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
BC Innovations | Jul 21, 2016
Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
BC Innovations | Feb 25, 2016
Strategy

Changing the channel

Having helped expose the reproducibility crisis about five years ago, Amgen Inc. is staying at the forefront of the issue with its support of F1000Research , an open-science platform to let researchers check each other's data....
BC Innovations | Dec 17, 2015
Translation in Brief

Old PKIS, new probes

Although there are over 500 kinases in the human genome, under 100 are being actively pursued as therapeutics, because of the lack of chemical probes needed to dissect their function. A public-private partnership headed by...
BC Innovations | Nov 5, 2015
Translation in Brief

Tapping malaria for TB

Academic researchers in Seattle have found a compound that could treat tuberculosis in chemical libraries from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The group teamed up with GSK's Tres Cantos Open Lab Foundation to screen compounds originally...
BC Innovations | Aug 20, 2015
Tools & Techniques

Probative value

The use of low-quality chemical probes in preclinical R&D and the use of probes in the wrong settings or concentrations are two of the main culprits behind unreliable preclinical results and failures in translational science,...
Items per page:
1 - 10 of 53
BC Extra | Oct 2, 2019
Preclinical News

New NIH centers to validate Alzheimer’s targets

As major biopharmas are scaling back Alzheimer’s disease programs following the spate of late-stage amyloid blowups, NIH is making a push for early stage drug discovery in the indication with the formation of two new...
BioCentury | Aug 31, 2019
Product Development

Privacy, transparency and consent

Patients need to control the use of their data. This calls for new policies on transparency and consent, and means establishing systems governing the ownership, collection and agency of those data. Data privacy is probably...
BC Innovations | Feb 8, 2018
Finance

External rethink

As the industry seeks to develop new ways to access external innovation, companies are re-evaluating the value of public-private partnerships, and increasingly turning to other companies for research partnerships in lieu of broad deals with...
BC Week In Review | Oct 6, 2017
Company News

Takeda, Karolinska Institute and Structural Genomics Consortium partner to treat IBD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Karolinska Institute (Stockholm, Sweden) and Structural Genomics Consortium (SGC) (Headington, U.K.) partnered to discover and validate new intervention points to treat inflammatory bowel disease (IBD). Under the deal, Takeda will...
BC Innovations | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
BC Innovations | Jul 21, 2016
Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
BC Innovations | Feb 25, 2016
Strategy

Changing the channel

Having helped expose the reproducibility crisis about five years ago, Amgen Inc. is staying at the forefront of the issue with its support of F1000Research , an open-science platform to let researchers check each other's data....
BC Innovations | Dec 17, 2015
Translation in Brief

Old PKIS, new probes

Although there are over 500 kinases in the human genome, under 100 are being actively pursued as therapeutics, because of the lack of chemical probes needed to dissect their function. A public-private partnership headed by...
BC Innovations | Nov 5, 2015
Translation in Brief

Tapping malaria for TB

Academic researchers in Seattle have found a compound that could treat tuberculosis in chemical libraries from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The group teamed up with GSK's Tres Cantos Open Lab Foundation to screen compounds originally...
BC Innovations | Aug 20, 2015
Tools & Techniques

Probative value

The use of low-quality chemical probes in preclinical R&D and the use of probes in the wrong settings or concentrations are two of the main culprits behind unreliable preclinical results and failures in translational science,...
Items per page:
1 - 10 of 53